| 本文已被：浏览 147次 下载 67次 |
码上扫一扫！ |
| 气管注入不同剂量布地奈德治疗新生儿急性呼吸窘迫综合征的前瞻
性研究 |
| 张崇巽,杨波,施鸿珊,徐思媛,王冰洁,李政,任漪,李敏,高翔羽 |
|
|
| ((徐州医科大学徐州临床学院,徐州市中心医院,江
苏徐州 221009)) |
|
| 摘要: |
| 目的:比较气管注入不同剂量布地奈德治疗新生儿急性呼吸窘迫综合征( NARDS) 的临床疗效和安全性。方法:选取
2022 年10 月至2024 年8 月徐州市中心医院收治的符合蒙特勒定义、出生胎龄≥34 周的NARDS 患儿,随机分为对照组、低剂量组
和常剂量组。对照组给予肺泡表面活性物质(PS),低剂量组给予布地奈德0. 10 mg/ kg+PS,常剂量组给予布地奈德0. 25 mg/ kg+
PS。结果:对照组呼吸支持时间长于低剂量组和常剂量组(P<0. 05)。3 组患儿使用特殊级抗生素、一氧化氮吸入率、机械通气
率、机械通气持续时间等比较差异均无统计学意义(P>0. 05)。气管注入药物后48 h,对照组氧合指数高于低剂量组和常剂量组
(P<0. 05)。3 组患儿治疗后并发症发生率比较差异均无统计学意义(P>0. 05)。结论:气管注入低剂量或常剂量布地奈德+PS 治
疗NARDS,均能缩短机械通气时间、降低注入后48 h 氧合指数,临床疗效相似,均优于仅注入PS,未明显增加不良反应。 |
| 关键词: 布地奈德 急性呼吸窘迫综合征 气管内给药 剂量 新生儿 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2025.07.002 |
|
| 基金项目:江苏省研究生实践创新计划项目,编号SJCX23_1401;徐州市科技局重点研发计划,编号KC22170。 |
|
| Prospective Study on the Treatment of Neonatal Acute Respiratory Distress Syndrome with Different Dosesof Budesonide via Intratracheal Administration |
| Zhang Chongxun, Yang Bo, Shi Hongshan, Xu Siyuan, Wang Bingjie, Li Zheng, Ren Yi, Li Min, Gao Xiangyu |
| ((Xuzhou Clinical College of Xuzhou Medical University, Xuzhou Central Hospital, Jiangsu Xuzhou 221009, China)) |
| Abstract: |
| Objective: To compare the clinical efficacy and safety of different doses of budesonide via intratracheal administration in the
treatment of neonatal acute respiratory distress syndrome (NARDS). Methods: From Oct. 2022 to Aug. 2024, children with NARDS
who meeting the Montreux definition and ⩾34 weeks of gestational age admitted into Xuzhou Central Hospital were randomly divided into
the control group, low-dose group and conventional dose group. The control group was given pulmonary surfactant (PS), the low-dose
group received budesonide 0. 10 mg/ kg + PS, and the conventional dose group was treated with budesonide 0. 25 mg/ kg + PS. Results:
The duration of respiratory support of control group was longer than that of low-dose group and conventional dose group (P<0. 05).
There were no statistical differences in use of special grade antibiotics, rate of nitric oxide inhalation, rate of mechanical ventilation, and
duration of mechanical ventilation among three groups (P>0. 05). The oxygenation indicators of control group were higher than those of
low-dose group and conventional dose group at 48 h after intratracheal administration (P<0. 05). There were no statistically differences
in incidence of complications among three groups (P>0. 05). Conclusion: Low-dose or conventional dose of budesonide + PS in the
treatment of NARDS can shorten the duration of respiratory support and reduce the oxygenation indicators at 48 h after intratracheal
administration, and the clinical efficacy is similar, both of which are better than PS alone, and there are no obvious increase in adverse
drug reactions. |
| Key words: budesonide acute respiratory distress syndrome intratracheal administration dose newborns |
